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Introduction: The most common cause of pulmonary hypertension (PH) in patients
is due to left heart failure (HF). Diagnosis of early stages of HF or PH have not
been clearly obvious, recently. Elevated filling pressures in the heart and pulmonary
vascular remodelling is associated with expression changes of the various plasma
levels of biomarkers.
Purpose: To assess the plasma levels of HF biomarkers on a new rodent model of
HF induced by the left ventricle pressure-overload which leads to the development
of reactive PH consist of pulmonary vascular remodelling.
Methods: The left heart failure was induced by pressure overload in adult male
Wistar rats by inserting a polyethylene tubing into aorta trough the right carotid
artery. Three weeks later experimental animals were studied (the group E, n=6)
and compared to the controls (n=6). Serial venous blood samples were taken
from both experimental groups to determine levels of biomarkers involved in
pathophysiology cardiac and vascular remodelling: Troponin I, N-proBNP, Copeptin,
Apelin, Endostatin, Asymmetric dimethylarginine (ADMA), Growth/differentiation
factor 15 (GDF-15), Ceruloplasmin and Cystatin-C. The biomarker levels were
assessed by ELISA method.
Results: The left ventricle end-diastolic pressure was elevated in the group E
(1.34±0.07 mmHg vs. 0.41±0.13 mmHg in the controls; p<0.0001). Mean pulmonary
arterial blood pressure measured by catheterization was increased 22.9±0.7 mmHg
compared to the controls 16.9±1.0 mmHg; p<0.05. Weight of the right ventricle
relative to body weight was 5.5±0.3.10-4 compared to the controls 4.6±0.2.10-4;
p<0.05. In lung histology, 74% of small pulmonary vessels had muscularized media
(24% in controls; p<0.01).
Elevated blood plasma levels of biomarkers in the group E compared to the controls
were found in: NT-proBNP (671.8±61.2 pg.mL-1 vs. 450.3±47.5 pg.mL-1; p<0.05;
respectively) and Copeptin (251.9±41 pg.mL-1 vs. 141.3±10.1 pg.mL-1; p<0.05;
respectively). Significantly decreased blood plasma levels of biomarkers in the
group E compared to the controls were found in the values of Apelin (4.0±0.09
ng.mL-1 vs. 4.3±0.05 ng.mL-1; p<0.05; respectively) and ADMA (12.1±0.5 mg.mL-1
vs. 15.3±0.8 mg.mL-1; p<0.05; respectively). We found no significant changes in
the blood plasma levels compared to the controls in the values of TnI, GDF-15,
Endostatin, Cystatin-C and Ceruloplasmin.
Conclusion: We develop a brand new rodent model of PH accompanied with pul-
monary vascular remodelling induced by left HF. Presented experimental model
was associated with increased concentration of biomarker of cardiac remodelling:
NT-proBNP and Copeptin and with decreased level of biomarkers that have protec-
tive effect against vascular remodelling: Apelin and ADMA.
Atherosclerosis, Cerebrovascular Diseases, Aneurysm,
Restenosis
23
Microwave spectrometry for coronary stent monitoring
S Susana Amoros Garcia De Valdecasas1; GGL Gonzalez-Lopez1; IJC Jimenez2;
LLJ Jofre1; ABG Bayes-Genis3; JT Tejada2; JOC O’callaghan Castella1; ORL
Rodriguez-Leor4; CGM Galvez-Monton3; 1Polytechnic University of Catalonia,
Barcelona, Spain; 2University of Barcelona, Grup de Magnetisme, Departament de
Física de la Matèria Condensada, Barcelona, Spain; 3Fundació Institut d’Investigació
en Ciències de la Salut Germans Trias i Pujol, ICREC Research Program, Barcelona,
Spain; 4Germans Trias i Pujol University Hospital, Servei de Cardiologia, Barcelona,
Spain;
Funding Acknowledgements: 20153530/31, 2017 SGR 00483, RD16/0011/0006,
CB16/11/00403, MDM-2016-0600, PI18/00256, PI18/00256, Sociedad Española de
Cardilogía
Background: Coronary artery disease (CAD) is the leading cause of death world-
wide, and percutaneous coronary intervention with stenting the most widely
performed procedure to treat CAD. However, current stent monitoring tech-
niques are invasive and/or ionizing. Microwave spectrometry (MWS) may provide
a non-invasive, non-ionizing and cost-effective alternative capable of detecting
stent-related pathologies before they cause fatal heart failure.
MWS response to monitor stent status
Purpose: To develop a new MWS-based technology to monitor coronary stents in
an in vivo swine model.
Methodology: First, using a new MWS device, an in vitro experiment was carried
out to demonstrate: (1) the ability of detecting the presence of a stent and (2) stent
fractures (SF). To that end, an intact stent was distanced 3, 7, 11 and 15 mm from a
MWS near-field probe in open-air conditions. Afterwards, three identical stents were
piecemeal cut to emulate type I, II and III SF at different fractions of the stent’s length
(l): l/5, l/3 or l/2. Additionally, the stent was measured in a phantom substance, to
simulate in vivo conditions: it was distanced from 0 to 40 mm in steps of 5 mm.
Likewise, a pair of MWS far-field antennas measured the stent at 10, 20, 30 and
40 mm.
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Background: The search for ideal responders to cardiac resynchronization therapy
(CRT) remains relevant and is widely discussed nowadays.
Purpose: To assess the echocardiographic response to CRT depending on the
myocardial dyssynchrony in patients with chronic heart failure (CHF) and permanent
atrial fibrillation (AF).
Methods: The study included 101 patients with CHF NYHA II – III, left ventricular
ejection fraction <35% and QRS≥130 ms. All patients underwent CRT. Then
atrioventricular node ablation was performed to 83 patients, but 18 patients refused
it. The criterion for the effectiveness of CRT was a decrease in the end-systolic
volume ≥15%. The survey was conducted initially, after 3 and 12 months from the
date of inclusion in the study. According to the results of the prospective observation
groups of patients with CHF and AF were formed in dependence on the duration and
sustainability of the response to CRT: 1a - early response (3 month) and preservation
of effect by 12 months, 1b - ‘elusive’ early effect, 2a - delayed response (12 month),
2b – non-responders.
Results: The study revealed the correlation between the increase in the presystolic
delay on the aortic valve and the delayed response to CRT that was confirmed by
the results of the frequency analysis of this interventricular delay. In groups 1a, 1b
and 2b the frequency of cases of presystolic delay on the aortic valve varied from
67% to 73%, but in group 2a it was 100%. We obtained similar results analyzing
dispersion of intraventricular contraction. In group 2a a variance of intraventricular
contraction of more than 100 ms was found in 90.5% of patients (no more than
70.0% of patients in the remaining groups).
Responders and non-responders significantly differed in the incidence of moderately
extended and wide QRS. Picture 1 demonstrates the incidence of QRS wide
(>150 ms) in patients with a different response to CRT. The results indicated the
dependence of the positive effect of CRT on the width of the QRS complex.
Conclusions: The early sustained response to CRT was more commonly detected
in NYHA II patients. There were more non-responders among those with NYHA III.
Patients with an early and sustained response to CRT were characterized by higher
median values of the 6-minute walk test. Diabetes mellitus was more often detected
in individuals with the ’escape’ of the early positive effect. A smaller proportion of
atrioventricular node ablation was found in the subgroup with an elusive effect, which
allows us to conclude that ablation of the AV compound increases the effectiveness
of CRT in individuals with AF.
QRS wide incidence and CRT response
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Introduction: Data on the safety and efficacy of preoperative levosimendan infusion
in patients undergoing left ventricular assist device (LVAD) implantation is scarce.
Purpose: To investigate the clinical utility of preoperative levosimendan administra-
tion in patients prior to LVAD implantation. Our hypothesis was that preoperative
levosimendan will be associated with improved post-operative outcomes due to
extended cardiovascular therapeutic effects from its long-acting active metabolites.
Methods: A retrospective analysis of all consecutive patients who received
continuous-flow LVADs (HeartMate 2, 3, and HVAD) between August 2012 and
May 2018 in a single tertiary center. INTERMACS profile 1 patients were excluded.
Patients who received preoperative levosimendan were compared to patients who
did not receive levosimendan preoperatively.
Results: The study cohort consisted of 62 patients (40 [65%] in the levosimendan
group and 22 [35%] in the no-levosimendan group) with a median follow-up of 21
months.
Preoperative laboratory parameters were similar in both groups except for lower
median albumin levels among patients in the levosimendan group (3.7 g/dL vs.
4 g/dL; P=0.024). Preoperative echocardiographic parameters, including left ven-
tricular ejection fraction, the presence of enlarged right ventricle (RV), moderate to
severe reduction in RV function and above moderate tricuspid regurgitation were
similar between the levosimendan and no-levosimendan groups (median of 15% vs.
17.5%; 18% vs. 7%; 52.5% vs. 40.9%; and 10% vs. 13.6%, respectively; p>0.1 for
all). Preoperative cardiac output, mean pulmonary artery and right atrium pressures
and pulmonary vascular resistance were also similar between the groups (median
of 2.93 L/min vs. 3.19 L/min; 41.5 mmHg vs. 33 mmHg; 10 mmHg vs. 8 mmHg; and
3.17 wood units vs. 4.02 wood units, respectively; p>0.1 for all). Preoperative median
pre-capillary wedge pressure was higher in the levosimendan group (28 mmHg vs.
23.5 mmHg; P=0.047).
No patient in either group required right ventricular assist device support. There
was no difference in post-operative inotropes and ventilation support time between
the levosimendan and no-levosimendan groups (median of 51 hours vs. 72 hours;
P=0.41 and 24 hours vs. 27 hours; P=0.19, respectively). Length of hospitalization,
both total and in the intensive care unit was similar (median of 13 days vs. 16 days;
P=0.34 and 3 days vs. 4 days; P=0.44, respectively).
Post-operative laboratory and echocardiographic parameters did not differ
between the groups. The in-hospital complication rate including bleeding, surgical
re-exploration and cardiac arrhythmias was also similar.
There was no significant difference in the in-hospital and long term mortality
throughout the follow-up period between the groups (2.5% vs. 4.5%; P>0.99 and
10% vs. 27.3% respectively; P=0.64).
Conclusion: Levosimendan infusion prior to LVAD implantation was not associated
with improved post-operative outcomes.
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Introduction: Exercise training is an excellent tool to promote functional capacity in
chronic heart failure (HF) patients. Although its benefits in this population, it needs to
be demonstrated in decompensated HF patients. A way to optimize an intervention
is to evaluate who are the good responders and understand the causes of no
response. Knowing the factors of good response is also important to emphasize
the feasibility of an intervention and to deliver it to the ones who get the most
benefit of it.
Purpose: To identify the characteristics that lead a patient to have a better response
to an aerobic exercise training program for decompensated HF inpatients – ERIC-HF
(early rehabilitation in cardiology – heart failure)
Methods: 50 patients who performed ERIC-HF program during the phase of sta-
bilization were evaluated in terms of their sociodemographic, functional and phys-
iological characteristics and performance during the program. The main variable
used to understand the performance of the patients was the variation of the dis-
tance walked in the 6-minute walking test (6MWT), performed as soon as the patient
were able to do it (6MWTinicial) and at discharge (6MWTdischarge). A multiple linear
regression was made in order to determine which variables are related to a better
variation on the 6MWT, namely: age, LCADL and Barthel index (BI) scores at admis-
sion and discharge, number of days of hospitalization, number of cardiovascular risk
factors, NYHA class, etiology of HF and ventricular function. Durbin-Watson test was
used to analyze the existence of independence of residual random variables. It was
assumed a significance level at p<0.05.
Results: Patient’s average age was 71 (±11) years old, 34 are male, 80% are in
NYHA class III and 73% have severe left ventricular depression. Patients present a
median of 76 points in BI at admission (minimum of 45 and maximum of 97) and
a median of 32 at LCADL (minimum of 24 and maximum of 45 points). The mean
distance walked in the 6MWTinicial performed by the patients was 199.9 (±115.9)
meters and 287.6 (±128.9) meters at 6MWTdischarge, representing a 87.7 (±170.6)
meters variation.
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According to the linear regression, an equation was obtained: Difference of
the 6MWT = 454.694-1*6MWTinitial+2.981*Barthelinitial-5.554*age. This equation
explains 65% of the variation of the model in this sample of patients. Using this vari-
ables it’s possible to know how much distance a patient can walk, and understand
if he is going to have a good performance in the program.
Conclusions: Patients with the worst results in the initial 6MWT, higher initial Barthel
and younger ages, will get the most gains in terms of difference walked between the
initial and final 6MWT and have the most benefit from the intervention program.
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Aim: The aim of this study was to evaluate changes in Ney York Heart Association
(NYHA) functional class, cardiopulmonary exercise test (CPET) variables, 6-min walk
test (6MWT) in patients (pts) submitted to percutaneous mitral valve repair with
MitraClip (MC).
Methods: Prospective analysis of 46 pts with moderate to severe mitral regurgitation
- MR - (grades III-IV) submitted to MC between 2013 and 2019 in our institution. The
Wilcoxon sign test was used to assess the procedure’s effect on NYHA Class, CPET
and 6MWT, by comparing several variables at baseline and at 1 year postprocedure
follow-up. P-values<0.05 were considered significant.
Results: 46pts, 61% male, with a mean age of 65±14 years (Y) and mean follow-up
time of 17±14 months, of which 58.7% presented with grade IV MR (mean regur-
gitant volume - 49.6±21 ml; mean EROA - 35.1±13 mm2 ) and 75% with func-
tional MR. Mean LVEF of 36%±11.8, with 55% presenting a LVEF <35%. Mean
Euroscore II of 6.0±7. 27.5% had already undergone a previous cardiac surgery,
in most cases CABG (63.6%). 34.8% had already suffered an acute coronary syn-
drome and 63% had atrial fibrillation. Mean pre-procedural peak oxygen uptake
(pVO2) of 14.3mL/kg/min and mean distance in the 6 minute walk test (6MWT) of
322±96m. Device implantation was successful in 45 pts with a device success rate
of 87% (successful implantation and reduction in MR to grade 2 or less), with 54%
of pts presenting mild MR before discharge. There were immediate complications
related to the procedure in 17.5% of pts, with 4pts experiencing tendinous cord rup-
ture and 2pts leaflet tear. There were no cases of pericardial tamponade or embolic
complications. Follow-up mortality of 34.8% (16pts), with 9 deaths in the first-year
post-procedure, 1 pt referred to cardiac surgery due leaflet tear and 1pt to heart
transplantation. Successful MC was associated with an improvement in pVO2 (14.3
vs 18.6 mL/kg/min, p=0.043), 6MWT distance (322.2m vs 373.2m, p=0.001) at 1 year
follow-up, irrespective of MR aetiology and left ventricular systolic function. It also
led to a an improvement in NYHA class both at 6 months (mean NYHA class: 2.9 vs
2.1, p=0.009) and 1 year post-procedure (mean NYHA class: 2.9 vs 2.0, p=0.001).
However, these improvements weren’t verified at the 1 and 6 months follow-up. MC
wasn’t associated with a reduction of neither the natriuretic peptide value (854.6 vs
450.1 pg/ml, p=0.241) nor the VE/VCO2 slope value (36.2 vs 34.1, p=0.144) at 1 year
follow-up.
Conclusion: Percutaneous mitral valve repair with MitraClip was associated with an
enhancement in cardiopulmonary performance and reduction in the symptomatic
burden after the first year post-procedure.
Chronic Heart Failure: Pharmacotherapy
P575
Prognostic impact of digoxin use in a heart failure population
JP Joao Pedro Dias Ferreira Reis1; A Goncalves1; P Bras1; R Ilhao Moreira1; T Pereira
Silva1; A Timoteo1; R Soares1; R Cruz Ferreira1; 1Hospital de Santa Marta, Lisbon,
Portugal;
Aim: Digoxin (D) may be considered in patients (pts) in sinus rhythm with symp-
tomatic HFrEF to reduce the risk of hospitalization and in pts with HFrEF and atrial
fibrillation (AF) for rate control. There are some controversies regarding its safety in
this population, with some studies suggesting a higher risk of events, while others
showed no deleterious effect on mortality.
Methods: Prospective evaluation of adult pts with HFrEF submitted to CPET in a
tertiary centre. Pts were followed up for at least 1 year for the primary endpoints of
cardiac death, urgent heart transplantation/ ventricular assist device implantation in
the first year of follow-up (MH1) and sudden cardiac death (SCD). Univariate followed
by Cox multivariate regression analysis were performed to evaluate the impact of D
use in the study’s endpoints. Survival analysis was performed using Kaplan-Meier
plots.
Results: CPET was performed in 487 HRrEF pts, with a mean age of 56.3 ±
12.5 years, of which 79.1% were male, 46.3% of ischemic aetiology (IA), with a
mean LVEF of 30.4 ± 7.6%, a mean heart failure survival score (HFss) of 8.6±1.1.
At baseline, 134 (29.3%) pts were receiving D. These pts presented lower LVEF
(26.7% vs 30.9%, p<0.001), HFss (8.3 vs 8.7, p<0.001) and sodium values (137.0
vs 138.3, p<0.001), a lower prevalence of coronary artery disease (38.8% vs 49.2%,
p=0.042), but a higher prevalence of AF (38.8% vs 19.8%, p<0.001). There was no
difference regarding patient’s age, prevalence of chronic kidney disease (CKD), peak
oxygen uptake (pVO2) or VE/VCO2 slope values. Baseline D use was independently
associated with an increased risk of SCD in our population (HR: 3.45; 95%CI
1.28-9.27, 0.014), aswell as in pts of IA (HR: 4.45, 95%CI 1.25-15.83, p=0.014)
and with CKD (HR: 15.57, 95%CI 1.97-123.02, p=0.009). There was no association
with SCD in pts of non-ischemic aetiology, preserved renal function and AF. Pts
taking D presented a significantly higher incidence of SCD (log rank p<0.001). D use
was not independently associated with MH1 in the general population (p=0.122 in
multivariate analysis), but it was in pts of IA (HR: 4.94, 95%CI 1.32-18.39, p=0.017).
Conclusion: In our HF population, D use was an independent predictor of SCD,
particularly in pts with coronary artery disease and CKD.
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Aims: The 2016 International Society for Heart Lung Transplantation listing criteria
for heart transplantation (HT) states that the peak volume of oxygen consumption
© 2020 The Authors
European Journal of Heart Failure © 2020 European Society of Cardiology, 22 (Suppl. S1), 2–415
